Home/Pipeline/JTT-861

JTT-861

Chronic heart failure

Phase2Active

Key Facts

Indication
Chronic heart failure
Phase
Phase2
Status
Active
Company

About Akros Pharma

Akros Pharma is a clinical-stage biotechnology company serving as the US development arm of Shionogi. Its pipeline consists of seven small molecule drug candidates, primarily in Phase 1 and Phase 2 trials, targeting autoimmune diseases, type 2 diabetes, chronic heart failure, neurodegenerative diseases, pulmonary arterial hypertension, and peripheral artery disease. The company leverages Shionogi's discovery engine and is led by a management team with deep expertise in clinical development, regulatory affairs, and intellectual property. As a private, subsidiary entity, its financial position and strategic direction are intrinsically linked to its parent company.

View full company profile

Other Chronic heart failure Drugs

DrugCompanyPhase
V‑LAP SystemVectorious Medical TechnologiesEarly Clinical (Investigational)